Patient characteristics
| Variable . | AML+13* . | Control Group* . | P . |
|---|---|---|---|
| No. of patients | 34 | 850 | |
| Median age, years (range) | 64 (43-80) | 59 (17-84) | .004 |
| Male sex, no. (%) | 24 (70) | 465 (55) | .08 |
| WBC count, G/l, median (range) | 10 (1-318) | 11 (0.1-365) | .64 |
| Hemoglobin, g/dl, median (range) | 8.9 (4.6-12.8) | 9.2 (2.9-17.2) | .2 |
| Platelet count, G/l, median (range) | 77 (1-399) | 54 (1-1760) | .23 |
| LDH (U/l), median (range) | 269 (155-1011) | 414 (115-11140) | .009 |
| BM blasts, %, median (range) | 80 (11-100) | 68 (11-100) | .02 |
| BM blasts at day 16, %, median (range) | 5 (0-85) | 9 (0-100) | .78 |
| Performance status (ECOG) ≥ 2 (%) | 8 (26) | 263 (34) | .44 |
| de novo AML (%) | 26 (76) | 646 (76) | 1.0 |
| Allogeneic transplantation, no. (%) | 6 (18) | 180 (21) | .83 |
| CR, no. (%) | 21 (62) | 471 (55) | .49 |
| Relapse, no. (%) | 18 (86) | 327 (69) | .14 |
| Deceased, no. (%) | 31 (91) | 644 (76) | .04 |
| Variable . | AML+13* . | Control Group* . | P . |
|---|---|---|---|
| No. of patients | 34 | 850 | |
| Median age, years (range) | 64 (43-80) | 59 (17-84) | .004 |
| Male sex, no. (%) | 24 (70) | 465 (55) | .08 |
| WBC count, G/l, median (range) | 10 (1-318) | 11 (0.1-365) | .64 |
| Hemoglobin, g/dl, median (range) | 8.9 (4.6-12.8) | 9.2 (2.9-17.2) | .2 |
| Platelet count, G/l, median (range) | 77 (1-399) | 54 (1-1760) | .23 |
| LDH (U/l), median (range) | 269 (155-1011) | 414 (115-11140) | .009 |
| BM blasts, %, median (range) | 80 (11-100) | 68 (11-100) | .02 |
| BM blasts at day 16, %, median (range) | 5 (0-85) | 9 (0-100) | .78 |
| Performance status (ECOG) ≥ 2 (%) | 8 (26) | 263 (34) | .44 |
| de novo AML (%) | 26 (76) | 646 (76) | 1.0 |
| Allogeneic transplantation, no. (%) | 6 (18) | 180 (21) | .83 |
| CR, no. (%) | 21 (62) | 471 (55) | .49 |
| Relapse, no. (%) | 18 (86) | 327 (69) | .14 |
| Deceased, no. (%) | 31 (91) | 644 (76) | .04 |
Significant P values are indicated in bold.
All patients were enrolled in the AMLCG-99 or SAL trials and received intensive induction treatment. All patients are classified as ELN Intermediate-II; AML+13: patients with isolated tri- or tetrasomy 13, additional aberrations of the sex chromosomes are allowed.